Merck Serono spin-off to start pivotal trial with novel diabetes drug
This article was originally published in Scrip
Executive Summary
A Phase II study of Poxel's imeglimin, a new drug candidate for the treatment of type 2 diabetes, has shown incremental efficacy as an add-on therapy to sitagliptin, in patients inadequately controlled by sitagliptin monotherapy.